大剂量倍他乐克治疗克山病的临床研究

  • 打印
  • 收藏
收藏成功


打开文本图片集

【摘要】目的:研究分析克山病治疗采用大剂量倍他乐克的临床功效。方法:2022年1月—2023年4月,克山病患者就诊50例,随机数字表划分,常规组使用沙库巴曲缬沙坦予以患者治疗,观察组使用大剂量倍他乐克予以患者治疗,分析疗效。结果:心脏指标数据统计,观察组患者经由治疗后改善于两组间更为显著(P

【关键词】大剂量倍他乐克;克山病;临床功效

Clinical study on high-dose betaloc in the treatment of Keshan disease

ZHAO Guohua

People’s Hospital of Jingchuan County, Pingliang City, Gansu Province, Jingchuan, Gansu 744300, China

【Abstract】Objective: To study and analyze the clinical efficacy of high-dose betaloc in the treatment of Keshan disease. Methods: From January 2022 to April 2023, 50 patients with Keshan disease were treated with a random number table. The conventional group was treated with sacubarta and valsartan, while the observation group was treated with high-dose betaloc. The therapeutic effect was analyzed.Results: the data of Cardiac Index in the observation group were improved more significantly than those in the two groups after treatment (P

【Key Words】High-dose betaloc; Keshan disease; Clinical efficacy

克山病又称地方性心肌病,该病以心脏扩大,心律失常为主要表现,患病后,除损害心功能外,人体脑、肺、肾等均将受累,易诱发栓塞性疾病,因此克山病患者在患病期间并发症发病率较高,且具有一定病死率,对患者机体健康、生命安全存极大影响性[1]。(剩余3831字)

目录
monitor